Bispecific Antibody Targets TIM-3 and CD39 for Cancer
Summary
The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.
What changed
This document is a publication of a patent application from the USPTO detailing a novel bispecific antibody. The antibody is engineered to bind to both the TIM-3 and CD39 antigens, which are involved in immune checkpoint inhibition. The described antibody or antibody derivative is intended to enhance the immune system's activity against cancer cells and is proposed for use in cancer therapy.
This patent application does not impose immediate regulatory obligations on pharmaceutical companies or drug manufacturers. However, it signifies potential future developments in cancer therapeutics. Companies involved in oncology drug development may wish to monitor the progress of this patent and similar research for competitive intelligence and potential licensing or collaboration opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BISPECIFIC ANTIBODY TO HUMAN TIM-3 AND HUMAN CD39, AND USE THEREOF
Application US20260085127A1 Kind: A1 Mar 26, 2026
Inventors
Norihiro NAKAMURA, Kanto NAKAJIMA, Yuji MISHIMA, Noriko MATSUMOTO
Abstract
An antibody or antibody derivative having a higher immune checkpoint inhibitory effect. The antibody or antibody derivative is capable of enhancing immune activity against cancer cells, and can be used to treat cancer. The antibody is a heterodimeric antibody or antibody derivative capable of binding to both the TIM-3 and CD39 antigens. The heterodimeric antibody or antibody derivative is capable of enhancing immune activity against cancer cells.
CPC Classifications
C07K 16/2896 A61K 38/00 A61P 35/00 C07K 16/46 G01N 33/5011 C07K 2317/24 C07K 2317/31 C07K 2317/565 C07K 2317/622 C07K 2317/732
Filing Date
2023-04-07
Application No.
18854355
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.